Skip to Content
Merck
  • Application of an open-chamber multi-channel microfluidic device to test chemotherapy drugs.

Application of an open-chamber multi-channel microfluidic device to test chemotherapy drugs.

Scientific reports (2020-11-25)
Hui-Sung Moon, Chang Eun Yoo, Sangmin Kim, Jeong Eon Lee, Woong-Yang Park
ABSTRACT

The use of precision medicine for chemotherapy requires the individualization of the therapeutic regimen for each patient. This approach improves treatment efficacy and reduces the probability of administering ineffective drugs. To ensure accurate decision-making in a timely manner, anticancer drug efficacy tests must be performed within a short timeframe using a small number of cancer cells. These requirements can be satisfied via microfluidics-based drug screening platforms, which are composed of complex fluidic channels and closed systems. Owing to their complexity, skilled manipulation is required. In this study, we developed a microfluidic platform, to accurately perform multiple drug efficacy tests using a small number of cells, which can be conducted via simple manipulation. As it is a small, open-chamber system, a minimal number of cells could be loaded through simple pipetting. Furthermore, the extracellular matrix gel inside the chamber provides an in vivo-like environment that enables the localized delivery of the drugs to spontaneously diffuse from the channels underneath the chamber without a pump, thereby efficiently and robustly testing the efficacy and resistance of multiple drugs. We demonstrated that this platform enabled the rapid and facile testing of multiple drugs using a small number of cells (~ 10,000) over a short period of time (~ 2 days). These results provide the possibility of using this powerful platform for selecting therapeutic medication, developing new drugs, and delivering personalized medicine to patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Imatinib mesylate, ≥98% (HPLC)
Supelco
Cyclophosphamide, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Imatinib